Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Decreases By 88.1%
Portage Biotech Inc. (NASDAQ:PRTG) experienced an 88.1% reduction in short interest in August, with 7,200 shares short sold as of August 15, down from 60,600 shares on July 31. Currently, only 0.1% of the company's stock is shorted. The average daily trading volume is 881,800 shares, resulting in a days-to-cover ratio of 0.0 days. Despite this, PRTG shares traded down 0.5% recently, with a market cap of $75 million and a P/E ratio of -0.77.
Portage Biotech Inc. (NASDAQ:PRTG - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 7,200 shares, a decrease of 88.1% from the July 31st total of 60,600 shares. Based on an average daily trading volume, of 881,800 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the company's stock are sold short.
Get Portage Biotech alerts:
Portage Biotech Stock Down 0.5 %
Shares of NASDAQ PRTG traded down $0.03 during midday trading on Tuesday, hitting $6.39. The stock had a trading volume of 834,279 shares, compared to its average volume of 356,332. The business's 50 day moving average is $3.70 and its 200-day moving average is $6.65. The company has a market cap of $113.75 million, a P/E ratio of -0.77 and a beta of 1.47. Portage Biotech has a 52 week low of $2.10 and a 52 week high of $61.99.
About Portage Biotech
(Get Free Report)Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
Featured Articles
- Five stocks we like better than Portage Biotech
- The Most Important Warren Buffett Stock for Investors: His Own
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What is the Euro STOXX 50 Index?
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Man who Predicted Biden’s Drop Out: “Prepare for “Kamala Crash” (From Paradigm Press) (Ad)
Should you invest $1,000 in Portage Biotech right now?
Before you consider Portage Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Portage Biotech wasn't on the list.
While Portage Biotech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
